POLICY STATEMENT:

I. Recombinant Platelet-Derived Growth Factors: Becaplermin gel, Regranex®

A. Based upon our criteria and assessment of peer-reviewed literature, recombinant human platelet-derived growth factor (Becaplermin gel) for topical administration has been medically proven to be effective and therefore medically appropriate when used as an adjunct to standard wound management for neuropathic diabetic ulcers extending into the subcutaneous tissue. Appropriate candidates should meet ALL of the following criteria:
1. Adequate tissue oxygenation, as measured by:
   a. a transcutaneous partial pressure of oxygen of 30 mm Hg or greater on the foot dorsum or at the margin of the ulcer, or
   b. an ankle-brachial blood pressure index (ABI) greater than 0.70 or ankle systolic pressure greater than 70 mm Hg
2. Full-thickness ulcer (ie, stage III or IV), extending through dermis into subcutaneous tissues
3. Participation in a wound management program, which includes sharp debridement, pressure relief (ie, non-weight bearing), and infection control.

B. Based upon our criteria and lack of peer-reviewed literature, Becaplermin gel has not been medically proven to be effective and is considered investigational for all of the following indications:
1. Ischemic diabetic ulcers
2. Venous stasis ulcers
3. Pressure ulcers
4. Ulcers not extending through the dermis into the subcutaneous tissue
5. Surgical wounds
6. Ulcerated perineal hemangiomas of infancy

II. Autologous Platelet-Derived Preparations: Basic Fibroblast Growth Factor (BFGF), Epidermal Growth Factor (EGF), Placental Angiogenic Growth Factors (PGF’s), and Platelet-Rich Plasma (PRP)

Based upon our criteria and lack of peer-reviewed literature, autologous platelet-derived preparations have not been medically proven to be effective and are considered investigational in the treatment of:
A. Chronic non-healing wounds
B. Surgical wounds
C. All other conditions including, but not limited to: arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis, and tendinopathy.

This policy does not address fibrin sealants.
Refer to Corporate Medical Policy #7.01.35 regarding Bioengineered Tissue Products for Wound Treatment and Surgical Interventions.
Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services.
POLICY GUIDELINES:

I. Patients are typically treated once daily for up to 20 weeks. Continuing Becaplermin treatment should be reconsidered if the ulcer is not reduced in size by 30% within 10 weeks of treatment or complete healing has not occurred in 20 weeks. When expected reduction in ulcer size occurs successfully, the treatment is continued until the ulcer is completely healed. The increase in rate of healing must be balanced with the potential for increased risk from cancer. Application of the gel may be performed by the patient in the home.

II. When purchased at a pharmacy, coverage for Becaplermin gel is dependent upon the member’s prescription drug coverage.

III. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

Growth Factors are polypeptides produced by cells during development and in response to injury. Owing to their effects on cell proliferation, growth factors have undergone extensive analyses to determine their usefulness as wound healing agents.

A recombinant human platelet-derived growth factor, Becaplermin gel/Regranex®, has biological activity similar to that of endogenous platelet-derived growth factor that includes promoting chemotactic recruitment and proliferation of cells involved in wound repair and enhancing of granulation tissue.

Examples of growth factors used in wound healing are:

I. Basic Fibroblast Growth Factor (BFGF),
II. Epidermal Growth Factor (EGF),
III. Placental Angiogenic Growth Factors (PGF’s), and
I. Platelet-Derived Growth Factor (PDGF).

Autologous platelet-derived growth factor is one of the polypeptides that control growth, differentiation, and activation of cell types essential for wound healing. The growth promoting activities of platelet-derived growth factor (PDGF) are thought to be deficient in chronic wounds. Autologous platelet-derived growth factor preparations have been proposed as an adjuvant therapy for wound healing and to enhance healing following various types of surgery (e.g., oral and maxillofacial surgery, dental implants, non-union fractures).

Platelet-rich plasma (PRP) preparations, which contain growth factors, have been proposed as a primary treatment of miscellaneous conditions, such as arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis and tendinopathy. The effectiveness of PDGF and PRP use, for these conditions, has not been demonstrated in the peer-reviewed literature.

RATIONALE:

Becaplermin (Regranex) gel has been approved by the FDA specifically for use in the treatment of chronic neuropathic diabetic ulcers of the lower extremities. Becaplermin gel, in conjunction with a good wound care program, has been found to improve health outcomes of patients with chronic neuropathic diabetic ulcers by producing complete wound healing and reducing the time to complete wound healing when compared to a good wound care program alone.

In 2008, the manufacturer of Regranex gel, Ortho-McNeil Pharmaceutical, added a black box warning to the labeling stating an increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of Regranex gel in a post-marketing retrospective cohort study. Regranex gel should only be used when the benefits can be expected to outweigh the risks, and Regranex gel should be used with caution in patients with known malignancy.

Available data are insufficient to permit positive conclusions regarding the use of Becaplermin gel for treatment of ulcers (e.g., ischemic diabetic ulcers, pressure ulcers, and venous ulcers), other than chronic neuropathic diabetic ulcers, or other non-healing wounds in the investigational setting.

Evidence is insufficient regarding the use of platelet-derived growth factors as a treatment of chronic non-healing wounds, surgical wounds, and other conditions, including but not limited to, arthritis, Dupuytren’s contracture, epicondylitis, plantar fasciitis, or tendinopathy.

Proprietary Information of Excellus Health Plan, Inc.
A 2015 statement by the American Academy of Orthopedic Surgeons states “Biologic therapies are becoming increasingly popular in orthopedics due to their potential to regenerate tissue and enhance bone healing. However, questions still remain about their efficacy and indications for use.”

Published studies provide mixed results regarding the use of PRP; with some showing benefit of the treatment while others show no or little benefit. Proof of the efficacy of PRP has not been demonstrated in clinical studies and further well-designed, randomized, controlled studies are needed before conclusion can be made.

The 2017 publication of the American Academy of Orthopedic Surgeons: Management of Osteoarthritis of the Hip Evidence-based Clinical Proactive Guideline they concluded that, “No high quality randomized controlled trials were available comparing the performance of IA injection of stem cells or prolotherapy to placebo. Three studies (Battaglia et al, Dallari et al) compared IA injections of platelet-rich plasma (PRP) versus HA or a combination of PRP and HA. However, no high quality studies comparing PRP with placebo were available for inclusion.”

**CODES:**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0232T (E/I)</td>
<td>Injection(s), platelet rich plasma, any tissue, including image guidance, harvesting and preparation when performed</td>
</tr>
<tr>
<td>G0460 (E/I)</td>
<td>Autologous platelet rich plasma for chronic wounds/ulcers including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment</td>
</tr>
<tr>
<td>P9020 (E/I)</td>
<td>Platelet rich plasma, each unit</td>
</tr>
<tr>
<td>S0157</td>
<td>Becaplermin gel 0.01%, 0.5 gm</td>
</tr>
<tr>
<td>S9055</td>
<td>Procuren or other growth factor preparation to promote wound healing</td>
</tr>
</tbody>
</table>

**NDC:**

| 50484-0810-15 | Becaplermin |

**ICD10:**

**Medically Appropriate codes for when criteria is met under Policy Statement IA:**

- E08.621 Diabetes mellitus due to underlying condition with foot ulcer
- E08.622 Diabetes mellitus due to underlying condition with other skin ulcer
- E09.621 Drug or chemical induced diabetes mellitus with foot ulcer
- E09.622 Drug or chemical induced diabetes mellitus with other skin ulcer
- E10.621 Type 1 diabetes mellitus with foot ulcer
- E10.622 Type 1 diabetes mellitus with other skin ulcer
- E11.621 Type 2 diabetes mellitus with foot ulcer
- E11.622 Type 2 diabetes mellitus with other skin ulcer
- E13.621 Other specified diabetes mellitus with foot ulcer
### ICD10:

**Investigational codes (See Policy Statement IB):**

<table>
<thead>
<tr>
<th>Code Range</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I70.231-I70.249</td>
<td>Atherosclerosis of native arteries of leg with ulceration (code range)</td>
</tr>
<tr>
<td>I70.331-I70.349</td>
<td>Atherosclerosis of unspecified type of bypass graft(s) of leg with ulceration (code range)</td>
</tr>
<tr>
<td>I70.431-I70.449</td>
<td>Atherosclerosis of autologous vein bypass graft(s) of the leg with ulceration (code range)</td>
</tr>
<tr>
<td>I70.531-I70.549</td>
<td>Atherosclerosis of nonautologous biological bypass graft(s) of the leg with ulceration (code range)</td>
</tr>
<tr>
<td>I70.631-I70.649</td>
<td>Atherosclerosis of nonbiological bypass graft(s) of the leg with ulceration (code range)</td>
</tr>
<tr>
<td>I70.731-I70.749</td>
<td>Atherosclerosis of other type of bypass graft(s) of the leg with ulceration (code range)</td>
</tr>
<tr>
<td>L97.101-L97.929</td>
<td>Non-pressure chronic ulcer of lower extremity (code range)</td>
</tr>
<tr>
<td>L89.30-L89.95</td>
<td>Pressure ulcers (code range)</td>
</tr>
</tbody>
</table>

### REFERENCES:


Proprietary Information of Excellus Health Plan, Inc.
<table>
<thead>
<tr>
<th>Subject: Growth Factors for Wound Healing and Other Conditions</th>
<th>Effective Date: 01/20/00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Number: 2.01.24</td>
<td>Revised Date: 07/19/01, 05/16/02, 04/24/03, 05/19/04, 07/21/05, 03/16/06, 01/18/07, 01/17/08, 01/15/09, 02/18/10, 02/17/11, 02/16/12, 02/21/13, 02/20/14, 01/22/15, 01/21/16, 03/16/17, 02/15/18</td>
</tr>
<tr>
<td>Category: Technology Assessment</td>
<td>Page: 6 of 7</td>
</tr>
</tbody>
</table>


**Key Words:**

Becaplermin, Growth factors, Regranex, Platelet derived growth factor, PDGF, Platelet-rich plasma.
There is currently a National Coverage Determination (NCD) for Blood-Derived Products for Chronic Non-Healing Wounds. Please refer to the following websites for Medicare Members:

http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=217&ncdver=5&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New-York+-+Entire+State&KeyWord=blood+derived+products&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAAABAAAAA%3d%3d&